News

• Tivozanib superior to sorafenib in renal cell cancer
• Published on Jan 30, 2012

Preliminary analysis of the TIVO-1 trial has shown that the new antivascular endothelial growth factor inhibitor tivozanib increases progression-free survival (PFS) significantly more than the multikinase inhibitor sorafenib in patients with advanced renal cell cancer.  

• NICE set against cabazitaxel
• Published on Jan 30, 2012

NICE looks set to adhere to its preliminary decision not to recommend cabazitaxel (Jevtana) as second-line therapy for hormone-refractory metastatic prostate cancer after failure of docetaxel-based chemotherapy.  

• Rare genetic link for prostate cancer
• Published on Jan 30, 2012

US scientists have identified a rare gene mutation strongly associated with the risk of developing prostate cancer (NEJM 2012;366:141–9).  

• Etravirine now in 200mg tablets
• Published on Jan 24, 2012

The antiretroviral etravirine (Intelence) is now available as 200mg tablets. (It was previously formulated only as 100mg tablets.) Manufacturer Janssen says the new tablet strength will reduce the pill burden from four to two per day. Both strengths can be taken dispersed in a glass of water.  

• Prostate cancer biomarker evidence retracted
• Published on Jan 24, 2012

The journal Urology has retracted the paper that provided key evidence that early prostate cancer antigen-2 (EPAC-2) is a reliable biomarker.